Theragenics strengthens brachytherapy partnership with GE's Oncura
This article was originally published in Clinica
Executive Summary
Prostate cancer treatment specialist Theragenics (Buford, Georgia) has strengthened its long-term partnership with GE Healthcare subsidiary Oncura by signing a new distribution agreement for the latter's OncoSeed brachytherapy product. Under the terms of the deal, Theragenics will distribute OncoSeed in North America on a non-exclusive basis for one year, 1 May. The agreement includes the options for additional one-year terms. OncoSeed is said to be the first seed used in prostate cancer treatments and widely considered to be the industry standard for iodine-125 based products, according to Theragenics.